Eli Lilly’s donanemab slows Alzheimer’s in phase 3 trial
The antibody drug donanemab, developed by the pharma giant Eli Lilly, has met all of its goals in a phase 3 trial for slowing cognitive decline in people with Alzheimer’s disease.
Archives for May 4, 2023
AbbVie feels biosimilar impact on Humira sales
In first quarter 2023 financials, the company reported a drop in net revenue of close 10%, as the impact of Humira biosimilar entry onto the market begins to bite.
Seres secures first approval of oral microbiome product
Seres, together with partners Nestle Health Science, receive approval for its microbiome therapeutic to prevent recurrence of C. difficile infection.
GSK’s Arexvy becomes first-ever approved RSV vaccine
After decades of respiratory syncytial virus (RSV) vaccine research, a vaccine candidate for RSV developed by GSK, Arexvy, has become the first of its kind to be approved globally.